Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, POB 8100, 4068 Stavanger, Norway.
Rheumatol Int. 2012 Apr;32(4):1049-53. doi: 10.1007/s00296-009-1349-x. Epub 2010 Jan 9.
After over 10 years of use of tumor necrosis factor-alpha (TNF-α) inhibitors, their side effects and complications are reasonably well documented. Recently, however, granulomatous reactions and cases of complete sarcoidosis have been reported, especially in patients treated with the TNF-α receptor protein, etanercept. This is intriguing because the TNF-α antibody drugs infliximab and adalimumab are reportedly used to treat sarcoidosis. We present three patients who developed sarcoidosis while on etanercept treatment, and discuss if possible differences in cytokine profiles and T regulatory cell function in patients taking different TNF-α inhibitors may explain this paradox.
经过 10 多年的肿瘤坏死因子-α（TNF-α）抑制剂的应用，其副作用和并发症已有充分的记录。然而，最近有肉芽肿反应和完全结节病的病例报告，尤其是在接受 TNF-α受体蛋白依那西普治疗的患者中。这很有趣，因为 TNF-α 抗体药物英夫利昔单抗和阿达木单抗据称可用于治疗结节病。我们介绍了 3 名在依那西普治疗期间发生结节病的患者，并讨论了接受不同 TNF-α抑制剂治疗的患者细胞因子谱和 T 调节细胞功能的可能差异是否可以解释这种矛盾。
